HK1212434A1 - Tnt based diagnosis of paroxysmal atrial fibrillation tnt - Google Patents

Tnt based diagnosis of paroxysmal atrial fibrillation tnt

Info

Publication number
HK1212434A1
HK1212434A1 HK16100057.2A HK16100057A HK1212434A1 HK 1212434 A1 HK1212434 A1 HK 1212434A1 HK 16100057 A HK16100057 A HK 16100057A HK 1212434 A1 HK1212434 A1 HK 1212434A1
Authority
HK
Hong Kong
Prior art keywords
tnt
atrial fibrillation
based diagnosis
paroxysmal atrial
paroxysmal
Prior art date
Application number
HK16100057.2A
Other languages
English (en)
Chinese (zh)
Inventor
Dirk Block
Roberto Latini
Serge Masson
Ursula-Henrike Wienhues-Thelen
Christian Zaugg
Andre Ziegler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47143752&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1212434(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1212434A1 publication Critical patent/HK1212434A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/326—Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK16100057.2A 2012-11-09 2016-01-06 Tnt based diagnosis of paroxysmal atrial fibrillation tnt HK1212434A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12191996 2012-11-09
PCT/EP2013/073476 WO2014072500A1 (en) 2012-11-09 2013-11-11 Tnt based diagnosis of paroxysmal atrial fibrillation

Publications (1)

Publication Number Publication Date
HK1212434A1 true HK1212434A1 (en) 2016-06-10

Family

ID=47143752

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16100057.2A HK1212434A1 (en) 2012-11-09 2016-01-06 Tnt based diagnosis of paroxysmal atrial fibrillation tnt
HK18115419.1A HK1256334A1 (zh) 2012-11-09 2018-12-03 陣發性心房纖顫的基於tnt的診斷

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18115419.1A HK1256334A1 (zh) 2012-11-09 2018-12-03 陣發性心房纖顫的基於tnt的診斷

Country Status (8)

Country Link
US (3) US20150233946A1 (de)
EP (1) EP2917736B1 (de)
JP (2) JP6366594B2 (de)
CN (2) CN104769436B (de)
CA (1) CA2886698C (de)
ES (1) ES2774288T3 (de)
HK (2) HK1212434A1 (de)
WO (1) WO2014072500A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201413081D0 (en) * 2014-07-23 2014-09-03 Univ Birmingham Markers for AF
US10231639B2 (en) 2016-04-19 2019-03-19 Roche Diagnostics Operations, Inc. Algorithm of NTproBNP and hand held ECG to detect arrhythmia in an elderly population
BR112018073214A2 (pt) * 2016-06-17 2019-04-16 F. Hoffmann-La Roche Ag métodos para a previsão do risco de recorrência da fibrilação atrial, para o diagnóstico de fibrilação atrial em um indivíduo, para o monitoramento de uma terapia e para a classificação da fibrilação e utilizações do biomarcador
ES2817087T3 (es) * 2016-08-04 2021-04-06 Hoffmann La Roche ESM-1 (endocan) circulante en la evaluación de la fibrilación auricular
BR112019026389A2 (pt) * 2017-06-13 2020-07-21 F. Hoffmann-La Roche Ag método para diagnosticar a fibrilação atrial paroxística, método para auxiliar no diagnóstico de fibrilação atrial paroxística e seus usos
KR102368403B1 (ko) * 2017-12-13 2022-02-25 에프. 호프만-라 로슈 아게 뇌졸중의 예측을 위한 순환하는 안지오포이에틴-2(Ang-2)와 인슐린-유사 성장 인자-결합 단백질 7(IGFBP7)
CN112888948A (zh) * 2018-08-10 2021-06-01 豪夫迈·罗氏有限公司 用于评定Afib相关性脑卒中的CES-2（羧酸酯酶-2）
KR20210046675A (ko) * 2018-08-16 2021-04-28 에프. 호프만-라 로슈 아게 심방 세동 및 항응고 요법의 평가에서 순환하는 tfpi-2 (조직인자경로 억제제 2)
WO2020039001A1 (en) * 2018-08-22 2020-02-27 Roche Diagnostics Gmbh Circulating spon-1 (spondin-1) in the assessment of atrial fibrillation
KR20210049829A (ko) * 2018-08-24 2021-05-06 에프. 호프만-라 로슈 아게 심방 세동의 사정에서 및 뇌졸중의 예측을 위한 순환하는 fgfbp-1 (섬유모세포 성장 인자-결합 단백질 1)
CN109871808B (zh) * 2019-02-21 2021-03-02 天津惊帆科技有限公司 房颤模型训练、检测方法和装置
EP3730942A1 (de) * 2019-04-26 2020-10-28 Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca Diagnosemarker für vorhofflimmern
WO2021118796A1 (en) * 2019-12-13 2021-06-17 Ischemia Care Llc Biomarkers for the diagnosis of atrial fibrillation cause of stroke
JP2023537749A (ja) 2020-08-14 2023-09-05 エフ． ホフマン－ラ ロシュ アーゲー 無症候性脳梗塞及び認知低下の評価のためのｉｇｆｂｐ７
WO2022069658A1 (en) 2020-09-30 2022-04-07 F. Hoffmann-La Roche Ag Circulating total-nt-probnp (glycosylated and unglycosylated nt-probnp) and its ratio with nt-probnp (unglycosylated nt-probnp) in the assessment of atrial fibrillation
US20230288436A1 (en) 2021-10-25 2023-09-14 Bionote, Inc. Antibodies binding specifically to nt-probnp and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
US7632647B2 (en) 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
EP1666881B1 (de) 2001-05-04 2010-02-17 Biosite Incorporated Diagnostische Marker der akuten koronaren Syndrome und ihre Verwendungen
CA2511501A1 (en) 2002-12-24 2004-07-15 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
CA2648382C (en) 2006-04-04 2016-10-11 Singulex, Inc. Methods and compositions for highly sensitive analysis of markers and detection of molecules
EP2318844A1 (de) * 2008-07-14 2011-05-11 Roche Diagnostics GmbH Multimarkerpanel zur diagnose, überwachung und auswahl der therapie für patienten mit herzinsuffizienz
JP2011530705A (ja) 2008-08-13 2011-12-22 エフ．ホフマン−ラ ロシュ アーゲー 肺塞栓症のためのＤダイマー、トロポニン、ＮＴ−ｐｒｏＢＮＰ
CA2757384A1 (en) * 2009-04-03 2010-10-07 Decode Genetics Ehf. Determination of genetic risk of atrial fibrillation and stroke associated with rs7193343 and correlated markers
EP2796874B1 (de) 2010-08-26 2017-03-08 Roche Diagnostics GmbH Verwendung von Biomarkern bei der Überwachung von Medikation in einem Patient mit Herzversagen
BR112014007007B1 (pt) 2011-10-17 2022-04-19 F. Hoffmann-La Roche Ag Método in-vitro para diferenciação precoce da apoplexia isquêmica cardioembólica, uso de uma troponina cardíaca e dispositivo de diferenciação precoce da apoplexia isquêmica cardioembólica

Also Published As

Publication number Publication date
JP6654668B2 (ja) 2020-02-26
CN108120837B (zh) 2021-06-22
CA2886698C (en) 2019-02-19
WO2014072500A1 (en) 2014-05-15
US20150233946A1 (en) 2015-08-20
US20170074892A1 (en) 2017-03-16
CA2886698A1 (en) 2014-05-15
EP2917736B1 (de) 2019-12-25
JP6366594B2 (ja) 2018-08-01
JP2016502659A (ja) 2016-01-28
HK1256334A1 (zh) 2019-09-20
US20230062697A1 (en) 2023-03-02
ES2774288T3 (es) 2020-07-20
CN108120837A (zh) 2018-06-05
CN104769436A (zh) 2015-07-08
JP2018151411A (ja) 2018-09-27
EP2917736A1 (de) 2015-09-16
CN104769436B (zh) 2018-01-26

Similar Documents

Publication Publication Date Title
HK1256334A1 (zh) 陣發性心房纖顫的基於tnt的診斷
HK1212388A1 (en) Methods of tissue generation
HK1212261A1 (en) Methods of tissue generation
EP2903509A4 (de) Tragbarer herzmonitor
HK1211844A1 (en) Treatment of pulmonary disease
EP2897522A4 (de) Physiologisches mapping für arrhythmie
EP2846701A4 (de) Indikator für rechten vorhof
IL227017A0 (en) Evaluation of ablation in real time from EKG signals.
EP2814995A4 (de) Titanlegierungen
IL229457B (en) Multi-channel ecg measurement
GB201321559D0 (en) Diagnosis of the condition of apparatus
EP2817061A4 (de) Verbesserte ablationstechniken zur behandlung von vorhofflimmern
IL225773A0 (en) Discovery of the activation time of the heart
EP2656779A4 (de) Endoskop
EP2836114A4 (de) Messung physiologischer gehirnparameter mittels bioimpedanz
EP2696751A4 (de) Elektrokardiographische beurteilung eines arrhythmierisikos
HK1211480A1 (en) External preparation for skin
GB2508667B (en) Diagnosis of the condition of apparatus
GB2500893B (en) Spirometer
EP2851005A4 (de) Detektionskopf für ein stethoskop
EP2712550A4 (de) Lanzette
PL2934437T3 (pl) Zastosowanie soli glinu w zwalczaniu potliwości pod wpływem stresu
AP2013008332A0 (en) Diagnostic probe
LT2883057T (lt) Širdies nepakankamumo diagnostika
GB201221046D0 (en) Method of diagnosis